scholarly journals Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

2017 ◽  
Vol 7 ◽  
Author(s):  
Nabil F. Saba
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Study ◽  
Randomized Phase Ii

scholarly journals A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

2014 ◽  
Vol 25 (9) ◽  
pp. 1813-1820 ◽  
Author(s):  
T.Y. Seiwert ◽  
J. Fayette ◽  
D. Cupissol ◽  
J.M. del Campo ◽  
P.M. Clement ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Study ◽  
Randomized Phase Ii ◽  
Recurrent Squamous Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document